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See Article, pages 589–594Hepatocellular carcinoma (HCC) is the third most
common cause of death from cancer in men and the
sixth most common cause in women [1]. The incidence
of HCC is currently increasing in the US [2]. Chronic
inﬂammatory liver disease caused by viral hepatitis is
the background of HCC in the majority of cases but also
alcoholic liver disease, non-alcoholic steatohepatitis,
and diabetes mellitus are important risk factors for
HCC [2]. The incidence of HCC is rising faster than
most other cancers owing to the increasing prevalence
of hepatitis B (HBV) and C (HCV) infection worldwide.
While the oncogenetic mechanism of hepatitis B is
thought to result from genomic instability following
integration of HBV DNA into the hepatocyte host gen-
ome, hepatocarcinogenesis of hepatitis C is related to
the necroinﬂammatory hepatic response to viral infec-
tion. Although, HCC is mostly present under cirrhotic
conditions, a minority of tumors occur in livers with
non-cirrhotic parenchyma.
An evolution in therapeutic techniques occurring
over the past 3 decades has broadened available treat-
ment options for patients with HCC. If HCC is localized
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chemoembolization.mary principle of therapy, which can be achieved by
nonsurgical and surgical therapies. Nonsurgical tech-
niques that have been shown to be eﬀective for local
tumor control include radiofrequency ablation (RFA),
cryoablation, percutaneous ethanol (EI) and acetic acid
injection, as well as transarterial chemoembolization
(TACE). All of these locoregional techniques result in
local tumor destruction without the need of tumor and
liver tissue removal. Although surgical removal either
via resection or orthotopic liver transplantation (OLT)
is considered today as the gold standard for HCC treat-
ment, only the minority (approximately 20%) of patients
are candidates for these therapies. The choice of the suit-
able treatment is not only dependent on the tumor stage
but also on the severity of the underlying liver disease.
Among the surgical treatments liver transplantation
achieves the best results but can be oﬀered only to a
small proportion of patients due to graft availability,
selection criteria, and high cost. Therefore, in specialized
centers, liver resection is the mainstay of surgical ther-
apy in patients with well preserved liver function
(Child-Pugh A-B) and absence of portal hypertension
[3–5].
In experienced hands surgical resection for HCC can
be performed safely with a mortality rate below 2% and
a 5-year postoperative survival rate of 40–70% [3,6,7].
On the other hand, percutaneous RFA and EI have been
shown to be eﬀective for local tumor control and do not
require general anesthesia and hospitalization [5,8,9].
These advantages have made both percutaneous tech-
niques popular and both entered clinical practice before
these therapies had been proven to be equivalent or
superior to hepatic resection in randomized controlledPublished by Elsevier B.V. All rights reserved.
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this technique has its clear limitations when the tumor
is located in close proximity to major vascular and bili-
ary structures regardless of the tumor size. However,
there is evidence from several studies, including three
RCTs, that indicate that percutaneous RFA is superior
to EI [10–12]. Since the introduction of percutaneous
ablation techniques, their eﬃciency compared to surgery
or ablation in the treatment for small HCC has been
debated. This question is addressed in the study by the
Liver Cancer Study Group of Japan that appears in
the current issue of this Journal [13]. In this large, pro-
spective study, 7185 patients with HCC were divided
into those undergoing hepatic resection (n = 2857) ver-
sus percutaneous ablation with RFA (n = 3022) or EI
(n = 1306) for HCC. The majority of patients had hep-
atitis C as the underlying liver disease. All patients
exhibited Child’s A or B liver function and had no more
than 3 tumors with each not larger than 3 cm in diame-
ter. The comparison of all three groups showed that the
time-to-recurrence rate was signiﬁcantly lower for the
resection group. Locoregional ablation by RFA or EI
was an independent predictor of poorer outcome in
terms of recurrence compared to resection in the multi-
variate analysis. Despite these favorable results for the
resection group, these ﬁndings had no impact on overall
survival that was comparable for all three groups. This
might be the result of the relatively short follow-up.
Although this is not a RCT, the strength of this studyTable 1
Studies comparing hepatic resection vs. local ablation for small HCC
Author, year Study type Study period Comparison
Vivarelli, 2004 Retrospective 1998–2002 Resection (n = 79)
vs. RFA (n = 79)
Hong, 2005 Retrospective 1999–2001 Resection (n = 93)
vs. RFA (n = 55)
Huang, 2005 RCT 1998–2002 Resection (n = 38)
vs. EI (n = 38)
Wakai, 2006 Retrospective 1990–2002 Resection (n = 85)
vs. Ablation (n = 64)
Chen, 2006 RCT 1999–2004 Resection (n = 90)
vs. RFA (n = 71)
Lupo, 2007 Retrospective 1999–2006 Resection (n = 42)
vs. RFA (n = 60)
Guglielmi, 2008 Retrospective 1996–2006 Resection (n = 91)
vs. RFA (n = 109)
Abu-Hilal, 2008 Matched cohort& 1991–2003 Resection (n = 34)
vs. RFA (n = 34)
Schwarz, 2008 SEER
database study
1998–2003 Resection (n = 426)
vs. Ablation# (n = 328
Current study,
2008
Prospective
survey study
2000–2003 Resection (n = 2,857)
vs. RFA (n = 3,022)
vs. EI (n = 1,306)
ND, not deﬁned; RCT, randomized controlled trial; SERR, surveillance, epid
injection; ICG-R15, indocyanine green retention at 15 min;
&, matched for
cryosurgery, and other ablation techniques; *, Milan criteria (single lesion 6is the large number of patients analyzed within a rela-
tively short study period (2000–2003) and the clear def-
inition of the degree of tumor extent. On the other hand,
this study also has signiﬁcant drawbacks which are
related to the nature of a survey study. Furthermore,
the comparative analysis showed that patients in the
resection group had better liver function reﬂected by
the Child-Pugh score and indocyanine green retention
at 15 min. This diﬀerence implies that the groups are
not homogenously comparable and associated with
some degree of selection bias.
There are many retrospective studies comparing
resection versus ablation for small HCC [14–19] (Table 1).
The majority of these studies used percutaneous RFA
and demonstrated better results for patients who undergo
resection [14–16,18,19]. However, a subgroup analysis of
smaller tumors (less than 2–3 cm) showed an equivalent
outcome for resection and RFA in three of these studies
[14,16,18]. Because of the retrospective and non-random-
ized nature of these studies, the ﬁndings have to be care-
fully interpreted due to the lower level of evidence.
Surprisingly, only two RCTs comparing resection and
ablation have been published so far [20,21] (Table 1).
The RCT by Huang et al. [20] used percutaneous EI as
the ablative method while RFA was used in the RCT by
Chen et al. [21]. Both studies showed equivalent recur-
rence and survival data for the resection and percutane-
ous ablation group. Despite the nature of a RCT, both
trials had signiﬁcant drawbacks. The trial by HuangTumor
number
Tumor
size
Liver function Outcome
ND ND Child A/B Better disease-free and
overall survival for resection
1 64 cm Child A Lower tumor recurrence for
resection
62 63 cm Child A/B Equivalent recurrence and
survival
ND 64 cm ND Lower tumor recurrence and
better survival for resection
1 65 cm Child A,
ICG-R15 < 30%
Equivalent overall and
disease-free survival
1 3-5 cm Child A/B Equivalent overall and
disease-free survival
ND 66 cm Child A/B Better disease-free and
overall survival for resection
1 1–5 cm Child A/B Better disease-free survival
for resection
)
Milan* Milan* ND Better overall survival for
resection
63 63 cm Child A/B Lower tumor recurrence for
resection
emiology, and end results; RFA, radiofrequency ablation; EI, ethanol
gender, age, tumor size, and Child-Pugh score; #, included RFA, EI,
5 cm, or no more than three lesions 63 cm).
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power calculation, while 19 of 90 patients (21%)whowere
randomized for ablation converted to liver resection in the
other RCT [21]. These facts demonstrate the need for fur-
ther RCTs comparing hepatic resection versus percutane-
ous ablation for small HCC in patients with preserved
liver function and absence of portal hypertension.
Another interesting series that was recently published
comes from the Surveillance, Epidemiology and End
Results (SEER) database [22] (Table 1). During the per-
iod of 1998–2003, patients with HCC within the Milan
criteria (single lesion 65 cm, or no more than three
lesions 63 cm) were selected based on absence of extra-
hepatic disease and vascular invasion. In this series, the
actuarial overall survival was compared for OLT
(n = 428), liver resection (n = 426), and ablation
(n = 328). As expected, OLT had the best outcome fol-
lowed by resection and locoregional ablation. Although
the 1-year survival rate was similar for resection and
ablation, resection had a signiﬁcant better long-term
survival compared to ablation. These ﬁndings were also
consistent with the multivariate analysis where resection
was superior to ablation. However, these ﬁndings have
to be interpreted carefully since the ablation group
was composed of diﬀerent techniques including RFA,
EI, cryosurgery, and other locoregional techniques.
Therefore, the exact value of each technique can not
be assessed against liver resection.
In conclusion, hepatic resection and local ablation
such as RFA and EI are eﬀective treatment modalities
for small HCC. Although two RCTs found equivalent
outcomes for resection and ablation (RFA, EI), there
is evidence from the large US [22] and Japanese series
[13] reviewed herein that resection oﬀers better outcome
than locoregional ablation. There is also evidence that
percutaneous RFA is superior to EI and should be pre-
ferred for the treatment of small HCC among available
ablation techniques. Since the majority of data comes
from retrospective studies, further RCTs are warranted
to deﬁne the exact value of resection and ablation for
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